Multiple hepatocellular carcinoma (HCC) is divided into two categories: intrahepatic metastasis (IM), which is a true relapse of HCC, and multicentric origin (MO), which is a second primary tumor. Clinical diagnosis of multiple HCC is usually made based on tumor location and/or time to recurrence; however, it is often difficult to distinguish the two types of multiple HCC. Using 41 matched pairs of multiple HCC specimens, we confirmed the accuracy of clinical diagnoses using exome sequence data and investigated the importance of discriminating the type of multiple HCC. Genomic analysis revealed that 18 (43.9%) patients diagnosed as having genomic IM had common mutations in a pair of HCC tumors with the main tumor of these patients being more progressive compared to those with genomic MO. The accuracy of clinical diagnosis based on lobe (Definition 1) and segment (Definition 2) were 68.3% and 78.0%, respectively. Intriguingly, recurrence ≥2 years after initial surgery for 3 patients was IM. The survival of patients with clinical IM was significantly shorter than for those with clinical MO based on both Definition 1 (P = 0.045) and Definition 2 (P = 0.043).
which are considered to be of multicentric origin (MO). Thus, multiple HCC can be divided into two categories according to the mechanism of carcinogenesis.
Clinical classification of multiple HCC is based on tumor location, 4 time to recurrence 5, 6 and background liver 7 ; however, it is difficult to clearly distinguish IM from MO using only those clinical parameters. Pathologically, well-differentiated HCC rarely develops IM, while small recurrent tumors are interpreted to be IM if their differentiation grade is moderate or poor, even though the possibility of MO cannot be completely excluded. Hepatocellular carcinoma exhibits a higher incidence of IM via portal vein invasion when macroscopic findings of the tumor are of simple nodular type with extranodular growth or of multinodular confluent type, even if in the early stage. 8 Therefore, the pathological diagnosis of multiple HCC is done based on differentiation grade or the gross type of the tumor. 2 In contrast to clinical and pathological diagnoses, molecular biological approaches are able to provide a definite diagnosis of IM or MO in multiple HCC. For instance, comparing the integration pattern of hepatitis B virus into the HCC genome by Southern blotting and/or PCR analysis allows for the differentiation of IM from MO. 9, 10 In addition, comparative genomic hybridization analysis, 9, 11 loss of heterozygosity analysis of DNA microsatellites 9, 12, 13 and identification of mitochondrial DNA mutations within the D-loop control region 14 have also been useful for identifying tumor clonality. Other diagnostic criteria that have been used are based on the promoter hypermethylation status of tumor suppressor genes. 15 Next-generation sequencing (NGS) technology is currently being used to identify specific mutation signatures of HCC. [16] [17] [18] This approach has been applied to accurately diagnose types of multiple HCC 19, 20 and has shown that whole-exome sequencing can be used to confidently classify all cases of multiple HCC, unlike targeted sequencing. 19 In addition to discriminating IM and MO, physical changes during cancer progression can also be elucidated in individuals. 20 However, the number of patients in these studies was relatively small due to the difficulty of molecular analysis, and, therefore, the clinical significance of differentiating IM from MO could not be determined.
In the current study, we performed whole-exome sequence analysis of paired HCC tumor specimens and adjacent non-tumorous liver specimens obtained from the same patients to diagnose multiple HCC as IM or MO. We also analyzed the discrepancies between genomic and clinical diagnoses. Furthermore, we compared the survival of patients with IM and those with MO and evaluated the value of accurate multiple HCC diagnosis.
| MATERIAL AND ME THODS

| Patients
The study group was comprised of patients with multiple HCC who underwent liver resection from January 2011 to December 2017 at the Department of Digestive Surgery, Nihon University, Tokyo, Japan. The study was approved by the institutional review boards of the Nihon University School of Medicine (protocol number; 131) and all participants provided written informed consent. In the case with three tumors in metachronous multiple HCC, the larger two tumors were analyzed for sequencing. Surgical specimens were immediately dissected into small pieces after liver resection, snap frozen in liquid nitrogen and stored at −80°C.
| Diagnosis of multiple hepatocellular carcinoma
Clinically, two definitions of multiple HCC were used in this study based on tumor location and time for recurrence. All cases of patients with metachronous multiple HCC were classified as MO if HCC relapsed 2 years or more after the initial operation. Patients with synchronous multiple HCC or recurrence within 2 years after the initial operation were considered to have IM if the tumors were located in the same lobe (Definition 1) or if the tumors were in the same segment proposed by Healey et al 21 (Definition 2). For HCC tumors located in the caudate lobe, the caval portion and process portion were defined as right lobe while the Spiegel portion was defined as left lobe. The main tumor in metachronous multiple HCC was defined as the tumor resected at initial resection or as the larger tumor in synchronous multiple HCC. Based on DNA sequencing data, two tumors from the same patient with common mutations were diagnosed as IM (genomic IM), while MO was diagnosed if there were no common mutations (genomic MO).
| DNA extraction
Genomic DNA was isolated from HCC tumor specimens and adjacent non-tumorous liver specimens using a QIAamp DNA Mini Kit (Qiagen) according to the manufacturer's protocols. Genomic DNA concentrations were determined using a Qubit dsDNA BR Assay Kit (Lifetechnologies). One microgram of genomic DNA from each sample was used for the whole-exome sequencing procedure. 
| Exome sequencing
| Mutation calling
To identify somatic mutations, we used the integrated genotyper software karkinos (http://github.com/genome-rcast/ karkinos) as described previously. 18 Briefly, variant allele frequencies of somatic mutation were adjusted using estimated tumor content ratios and filtered with a heuristic filtering algorithm and Fisher's exact test. Variants with allele frequency ≥15%, read depth of tumor ≥15, depth of normal ≥10 and variant read ≥3 were retained. The contribution of known mutational signatures for each sample was determined using the deconstructSigs Catalogue of Somatic Mutations in Cancer (COSMIC) mutational signatures v2. 23 
| P-values for driver mutations
Driver mutation probabilities were calculated for each gene. An initial probability for observing a recurrent somatic mutation on the same gene was calculated using a binomial probability equation with gene length and background mutation rates. 18 False discovery rates were calculated by simulation as described previously. 18 
| Statistical analysis
Fisher's exact test for categorical variables and Student's t-test
and Wilcoxon rank sum test for continuous variables were used to assess the statistical significance of the data collected from early and classical HCC groups. For patients with metachronous HCC, survival time was defined as the period from the second operation to the date of death. Survival curves were generated using the Kaplan-Meier product-limit estimator and were compared using the log-rank test. Statistical significance was set at P < 0.05. In contrast, we collected "metachronous multiple HCC" samples (n = 21) from 103 patients who underwent the second resection.
| RE SULTS
| Patient enrollment
During the follow-up period at the outpatient clinic (from January 2011 to June 2019), 404 patients (48.9%) out of 825 HCC patients relapsed.
| Clinical diagnosis
Of the 41 patients that underwent curative liver resection for multiple HCC and were included in our study ( Figure Total 138.9 ± 57.9 131.2 ± 61.9 0.565
| Genomic diagnosis
Note: Data was shown as average with standard deviation.
Abbreviations: HCC, hepatocellular carcinoma; IM, intrahepatic metastasis; MO, multicentric origin; SNV, single nucleotide variation.
| Clinical characteristics
The main tumor was more progressive in patients with genomic IM compared to those with genomic MO based on significantly higher alpha-fetoprotein levels (P = 0.044), larger tumor size (P = 0.019) and frequent vascular invasion (P = 0.027) ( Table 2 ). In contrast, liver cirrhosis and liver function, including indocyanine green clearance rate at 15 minutes and frequency of Child-Pugh A classification, were not significantly different between the two groups.
| Mutation landscape
Exome sequence analysis revealed that several driver genes in genomic IM and MC, including CTNNB1 (33.3% vs 36.9%, P = 0.817), TP53 (27.7% vs 28.2%, P = 1.000), ARID2 (13.8% vs 10.8%, P = 0.742), MLL3 (11.1% vs 10.8%, P = 1.000) and ARID1A (13.8% vs 6.5%, P = 0.290), were more frequently mutated than expected by chance ( Figure 4A ). Ten patients with genomic IM had mutations in these driver genes in only one of the tumors (4 in CTNNB1, 2 in TP53, 1 in ARID2, 1 in MLL3 and 1 in ARID1A). The mutations were detected in metastatic tumors of five of the 10 patients (Table S2 ). However, one or two copies, which were below threshold, were detected in the main nodules, suggesting that a small number of cancer cells with these driver mutations metastasized to the other sites of the liver parenchyma ( Figure 4B ). In contrast, 4 of 23 patients with genomic MO had the same driver gene mutations in both tumors (2 in CTNNB1, 1 in TP53 and 1 in MLL3 genes), but the chromosomal positions of the mutation differed between the two tumors ( Figure 4C ). Figure 6C ). The
| Mutational signatures
| Survival
3-year rates of overall survival were 50.7% and 75.0%, respectively, in the two groups. To avoid survivor treatment bias, we also compared the overall survival results from the initial resection. There was no significant difference between the patients with genomic IM (median, 3.7 years [95% CI, 1.5-NA]) and those with genomic MO (6.3 years [95% CI, 2.7-NA], P = 0.486) ( Figure 6D ). 
TA B L E 2 Patient background
| D ISCUSS I ON
Clinically, the determination of IM and MO for patients with multiple HCC is based on tumor location and time to recurrence.
However, our current findings showed that the clinical diagnosis of multiple HCC was not very accurate, which was verified by molecular biological analysis. Consequently, we found that liver cancer cells were able to spread more extensively and more slowly than previously known. We also found that the type of multiple HCC did not necessarily reflect patient survival following tumor resection.
It is generally assumed that liver cancer cells metastasize along the portal vein to other sites of the liver parenchyma 1 and, therefore, satellite lesions within the same segment are likely to be IM.
However, genomic diagnosis revealed that tumor size was larger and vascular invasion was more frequent in IM, suggesting that IM could result due to tumor progression. Our data also showed that liver cancer cells frequently metastasized, regardless of the region of the liver. Given that IM could be detected even 2 years post-surgery, it is difficult to determine whether multiple HCC is actually IM or if it is a result of the clinical course. In contrast, most pairs of multiple nodules with different differentiation grade were diagnosed as genomic MO; therefore, histological findings after surgery were available for diagnosis of multiple HCC only when differentiation grades were different between the two nodules.
It was previously reported that MO is associated with poor liver function, 5, 7, 24 and, therefore, such lesions may not be a target for locoregional therapy but rather may be a signaling lesion for advanced stage chronic liver disease because patient survival depends in part on liver function. 25, 26 In contrast to the clinical observation, in the current study liver function, including the frequency of liver cirrhosis, was not significantly different between the two groups, and patient survival after the operation was not significantly different between the MO and IM groups. Therefore, patients with multiple HCC may still be candidates for resection, even for patients with MO HCC. 24 Similar to previous sequence data, [16] [17] [18] driver genes such as CTNNB1, TP53, ARID2, MLL3 and ARID1A were frequently ) indicates that the driver mutation was present in both patient tumors. B, Genome viewer revealed that a metastatic nodule had multiple copies of a mutation, beyond the threshold, while the main tumor harbored only one copy, which was below the threshold for a mutation-positive signal at the same position in CTNNB1. C, Genome viewer revealed that a pair of samples had mutation at different positions in CTNNB1 mutated in multiple HCC and there was no significant difference in the frequency of gene mutations between IM and MO samples.
Consequently, we failed to identify any genes responsible for IM.
The frequency of common mutations in 18 genomic IM samples was only 43%. However, several primary lesions harbored one or two copies of the same mutation that were found in metastatic lesions, which indicated that a small population of cancer cells with malignant potential could metastasize to other sites of the and time-dependent bias. 36 To avoid the bias, tumor samples should have been collected prospectively, or the tumor stage of the main tumor should have been established.
In conclusion, exome sequencing was able to be used to discriminate multiple HCC as IM or MO and it became clear that liver cancer cells could spread more extensively and more slowly than previously thought. Given that the overall survival of patients with IM and MO did not differ, the accurate classification of multiple HCC is not clinically important.
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